Mind Medicine

Mind Medicine in its US$30 million public offering


Mind Medicine


US$30 million


Capital Markets

Date Closed

September 2022


Pharmaceuticals and Life Sciences

Lead Office



On September 30, 2022, Mind Medicine (MindMed) Inc. issued 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares in an underwritten public offering for gross proceeds of approximately US$30 million.

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders.

Osler, Hoskin & Harcourt LLP acted as Canadian counsel to MindMed with a team consisting of Trevor Scott, Minji Park, Natalie Holtby (Corporate), Timothy Hughes and James Chang (Tax).